Evidence map›Paper›PMID 40592963›Full record

ArticleScientific reports2025

Esophageal cancer trends in the US from 1992 to 2019 with projections to 2044 using SEER data.

Zhaomin Xie, Jiajia Lin, Zihuan Li, Hexing Sun, Kaiyuan Huang, Danping Lin, Yingsheng Xiao, Congzhu Li, De Zeng

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zhaomin Xie *Department of Medical Oncology, Cancer Hospital of Shantou University Medical College, No. 7 Raoping Road, Shantou, 515041, Guangdong, People's Republic of China.
Jiajia Lin *School of Public Health, Shantou University, Shantou, 515041, People's Republic of China.
Zihuan LiHospital Infection Management Department, Guangdong Second Provincial General Hospital, Guangzhou, People's Republic of China.
Hexing SunDepartment of Breast and Thyroid Surgery, The First Affiliated Hospital of Shantou University Medical College, No.57 Changping Road, Shantou, 515041, Guangdong, People's Republic of China.
Kaiyuan HuangDepartment of Breast and Thyroid Surgery, The First Affiliated Hospital of Shantou University Medical College, No.57 Changping Road, Shantou, 515041, Guangdong, People's Republic of China.
Danping LinDepartment of Medical Oncology, Cancer Hospital of Shantou University Medical College, No. 7 Raoping Road, Shantou, 515041, Guangdong, People's Republic of China.
Yingsheng XiaoDepartment of Thyroid Surgery, Shantou Central Hospital, Shantou, People's Republic of China.
Congzhu LiDepartment of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Shantou, 515041, Guangdong, People's Republic of China. czli2013@163.cn.
De ZengDepartment of Medical Oncology, Cancer Hospital of Shantou University Medical College, No. 7 Raoping Road, Shantou, 515041, Guangdong, People's Republic of China. dezeng@stu.edu.cn.ORCID http://orcid.org/0000-0002-9141-5505

Funding

Guangdong Basic and Applied Basic Research Foundation No. 2022A1515012623Guangdong Basic and Applied Basic Research Foundation No. 2023A1515010616Guangdong Provincial Medical Science and Technology Research Fund Project No. A2021255Science and Technology Special Fund of Guangdong Province of China 190829105556145Strategic and Special Fund for Science and Technology Innovation of Guangdong Province of China 180918114960704
6 · The paper itself

Abstract

Esophageal adenocarcinoma (EAC) has increased substantially to become the most common type of esophageal cancer in the United States, surpassing esophageal squamous cell carcinoma (ESCC). Whether the increasing incidence of EAC is linked to trends in esophageal cancer mortality is unclear. We analyzed esophageal cancer data from the Surveillance, Epidemiology, and End Results-12 cancer registry program, using Joinpoint regression for trend analysis and a decomposition method to attribute changes to population growth, population aging, and epidemiological changes. Age-period-cohort models were employed to estimate incidence and mortality through 2044. Between 1992 and 2019, 39,700 individuals were diagnosed with esophageal cancer, and 35,259 deaths were recorded from 1993 to 2019. The overall incidence of esophageal cancer declined [average annual percent change (AAPC), - 0.7%], but the incidence of EAC increased by an AAPC of 1.6% per year (P < 0.001) from 1992 to 2019. The overall mortality rates decreased by an annual percentage change of 1.0% [95% confidence intervals - 1.2% to - 0.7%] from 1998 to 2019, primarily related to decline in ESCC in 1996-2019. The mortality of EAC increased by an AAPC of 2.2% per year (P < 0.001) over the study period and increased for all demographic characteristic groups. Population aging and growth largely explain the increase in esophageal cancer over the last 3 decades. Future projections (2019-2044) suggest a 31% increase in incidence and deaths, with EAC rates continuing to rise (AAPC, 0.25; 95% CI 0.23-0.28). The number of esophageal cancer cases and deaths have significantly increased and projections indicate that this trend will continue. Effective measures must be taken to address the burden of esophageal cancer.

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaAdultAgedAged, 80 and overFemaleHumansIncidenceMaleMiddle AgedSEER ProgramUnited StatesAgingEsophageal cancerIncidenceIncidence-based mortalityTrends

Identifiers

PMID40592963
PMCPMC12218057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.